Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men : a randomized, placebo-controlled study. Commentary
Identifieur interne : 009F83 ( Main/Exploration ); précédent : 009F82; suivant : 009F84Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men : a randomized, placebo-controlled study. Commentary
Auteurs : Patrick W. G. Mallon [Australie] ; John Miller [Australie] ; Jason C. Kovacic [Australie] ; Julia Kent-Hughes [Australie] ; Richard Norris [Australie] ; Katherine Samaras [Australie, France] ; Michael P. Feneley [Australie] ; David A. Cooper [Australie] ; Andrew Carr [Australie] ; Shahin Gharakhanian [France, États-Unis] ; Franck Boccara [France] ; Jacqueline Capeau [France]Source :
- AIDS : (London) [ 0269-9370 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Objectives: To determine the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on markers of cardiovascular risk and lipodystrophy in HIV-infected, protease inhibitor (Pl)-treated men with hypercholesterolaemia. Methods: A randomized, placebo-controlled, 16-week study was carried out on 33 HIV-infected, hypercholesterolaemic men (fasting total cholesterol > 6.5mmol/L) on PI-containing therapy. Patients commenced dietary assessment and advice at week 0 and were randomized to 12 weeks pravastatin (40 mg each night) or placebo from week 4. The primary endpoint was the time-weighted change (TWAUC) in total cholesterol from week 0. Secondary endpoints included TWAUC cholesterol from week 4 (start of pravastatin), total and regional body fat, fasting lipids, glucose, insulin, and markers of cardiovascular risk. Results: Of 33 men randomized (pravastatin n = 16, mean age 48 years), 31 completed the study. Groups were matched for baseline cholesterol and body composition. Although there was no significant between-group difference in TWAUC cholesterol from week 0 (pravastatin -0.6 ± 1.0 versus placebo -0.4 ± 1.0 mmol/L/week; P = 0.8), TWAUC cholesterol from week 4 decreased more in the pravastatin group (-0.8 ± 1.0 versus -0.3 ± 0.9 mmol/L/week; P = 0.04). Neither triglycerides nor dietary intake changed. Subcutaneous fat increased significantly with pravastatin (+0.72 ± 1.55 versus +0.19 ± 0.48 kg change in limb fat, P < 0.04; +5.2 ± 8.7 versus -1.3 ± 13.7 cm2 change in abdominal subcutaneous fat, P = 0.02). Apart from homocystine, which decreased in the pravastatin group, there were no significant differences in other cardiovascular, lipid or glucose parameters. Conclusions: Despite limited effects on cholesterol, 12 weeks use of pravastatin 40 mg each night in HIV-infected men with hypercholesterolaemia resulted in significant increases in subcutaneous fat.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 004417
- to stream PascalFrancis, to step Curation: 001C78
- to stream PascalFrancis, to step Checkpoint: 004085
- to stream Main, to step Merge: 00AB07
- to stream Main, to step Curation: 009F83
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men : a randomized, placebo-controlled study. Commentary</title><author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W. G." last="Mallon">Patrick W. G. Mallon</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>National Centre in HIV Epidemiology and Clinical Research, University of New South Wales</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Miller, John" sort="Miller, John" uniqKey="Miller J" first="John" last="Miller">John Miller</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Kovacic, Jason C" sort="Kovacic, Jason C" uniqKey="Kovacic J" first="Jason C." last="Kovacic">Jason C. Kovacic</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Cardiology, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Kent Hughes, Julia" sort="Kent Hughes, Julia" uniqKey="Kent Hughes J" first="Julia" last="Kent-Hughes">Julia Kent-Hughes</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Norris, Richard" sort="Norris, Richard" uniqKey="Norris R" first="Richard" last="Norris">Richard Norris</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Samaras, Katherine" sort="Samaras, Katherine" uniqKey="Samaras K" first="Katherine" last="Samaras">Katherine Samaras</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Garvan Institute of Medical Research</s1><s2>Sydney</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>AP-HP Department of Infectious Diseases, Tenon University Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Feneley, Michael P" sort="Feneley, Michael P" uniqKey="Feneley M" first="Michael P." last="Feneley">Michael P. Feneley</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Cardiology, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A." last="Cooper">David A. Cooper</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>National Centre in HIV Epidemiology and Clinical Research, University of New South Wales</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Carr, Andrew" sort="Carr, Andrew" uniqKey="Carr A" first="Andrew" last="Carr">Andrew Carr</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Gharakhanian, Shahin" sort="Gharakhanian, Shahin" uniqKey="Gharakhanian S" first="Shahin" last="Gharakhanian">Shahin Gharakhanian</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>AP-HP Department of Infectious Diseases, Tenon University Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Drug Evaluation & Approval, Vertex Pharmaceuticals</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Boccara, Franck" sort="Boccara, Franck" uniqKey="Boccara F" first="Franck" last="Boccara">Franck Boccara</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>AP-HP Department of Cardiology, Saint Antoine University Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Capeau, Jacqueline" sort="Capeau, Jacqueline" uniqKey="Capeau J" first="Jacqueline" last="Capeau">Jacqueline Capeau</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>INSERM U680</s1><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>INSERM U680</wicri:noRegion><wicri:noRegion>INSERM U680</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Pierre & Marie Curie School of Medicine</s1><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Pierre & Marie Curie School of Medicine</wicri:noRegion><wicri:noRegion>Pierre & Marie Curie School of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>UPMC and AP-HP</s1><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>UPMC and AP-HP</wicri:noRegion><wicri:noRegion>UPMC and AP-HP</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Biochemistry, Tenon University Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0243815</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0243815 INIST</idno><idno type="RBID">Pascal:06-0243815</idno><idno type="wicri:Area/PascalFrancis/Corpus">004417</idno><idno type="wicri:Area/PascalFrancis/Curation">001C78</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">004085</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004085</idno><idno type="wicri:doubleKey">0269-9370:2006:Mallon P:effect:of:pravastatin</idno><idno type="wicri:Area/Main/Merge">00AB07</idno><idno type="wicri:Area/Main/Curation">009F83</idno><idno type="wicri:Area/Main/Exploration">009F83</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men : a randomized, placebo-controlled study. Commentary</title><author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W. G." last="Mallon">Patrick W. G. Mallon</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>National Centre in HIV Epidemiology and Clinical Research, University of New South Wales</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Miller, John" sort="Miller, John" uniqKey="Miller J" first="John" last="Miller">John Miller</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Kovacic, Jason C" sort="Kovacic, Jason C" uniqKey="Kovacic J" first="Jason C." last="Kovacic">Jason C. Kovacic</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Cardiology, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Kent Hughes, Julia" sort="Kent Hughes, Julia" uniqKey="Kent Hughes J" first="Julia" last="Kent-Hughes">Julia Kent-Hughes</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Norris, Richard" sort="Norris, Richard" uniqKey="Norris R" first="Richard" last="Norris">Richard Norris</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Samaras, Katherine" sort="Samaras, Katherine" uniqKey="Samaras K" first="Katherine" last="Samaras">Katherine Samaras</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Garvan Institute of Medical Research</s1><s2>Sydney</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>AP-HP Department of Infectious Diseases, Tenon University Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Feneley, Michael P" sort="Feneley, Michael P" uniqKey="Feneley M" first="Michael P." last="Feneley">Michael P. Feneley</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Cardiology, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A." last="Cooper">David A. Cooper</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>National Centre in HIV Epidemiology and Clinical Research, University of New South Wales</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Carr, Andrew" sort="Carr, Andrew" uniqKey="Carr A" first="Andrew" last="Carr">Andrew Carr</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Gharakhanian, Shahin" sort="Gharakhanian, Shahin" uniqKey="Gharakhanian S" first="Shahin" last="Gharakhanian">Shahin Gharakhanian</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>AP-HP Department of Infectious Diseases, Tenon University Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>6 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Drug Evaluation & Approval, Vertex Pharmaceuticals</s1><s2>Cambridge, Massachusetts</s2><s3>USA</s3><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Boccara, Franck" sort="Boccara, Franck" uniqKey="Boccara F" first="Franck" last="Boccara">Franck Boccara</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>AP-HP Department of Cardiology, Saint Antoine University Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Capeau, Jacqueline" sort="Capeau, Jacqueline" uniqKey="Capeau J" first="Jacqueline" last="Capeau">Jacqueline Capeau</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>INSERM U680</s1><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>INSERM U680</wicri:noRegion><wicri:noRegion>INSERM U680</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Pierre & Marie Curie School of Medicine</s1><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Pierre & Marie Curie School of Medicine</wicri:noRegion><wicri:noRegion>Pierre & Marie Curie School of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>UPMC and AP-HP</s1><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>UPMC and AP-HP</wicri:noRegion><wicri:noRegion>UPMC and AP-HP</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Biochemistry, Tenon University Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">AIDS : (London)</title><title level="j" type="abbreviated">AIDS : (Lond.)</title><idno type="ISSN">0269-9370</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">AIDS : (London)</title><title level="j" type="abbreviated">AIDS : (Lond.)</title><idno type="ISSN">0269-9370</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Antilipemic agent</term><term>Antiretroviral agent</term><term>Antiviral</term><term>Atherosclerosis</term><term>Body composition</term><term>Cardiovascular disease</term><term>HMG</term><term>Human</term><term>Hyperlipemia</term><term>Lipids</term><term>Lipodystrophy</term><term>Male</term><term>Pravastatin</term><term>Statin derivative</term><term>Toxicity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Appareil circulatoire pathologie</term><term>SIDA</term><term>Lipodystrophie</term><term>Pravastatine</term><term>Statine dérivé</term><term>Antiviral</term><term>Composition corporelle</term><term>Mâle</term><term>HMG</term><term>Homme</term><term>Toxicité</term><term>Antirétroviral</term><term>Hyperlipémie</term><term>Athérosclérose</term><term>Hypolipémiant</term><term>Lipide</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives: To determine the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on markers of cardiovascular risk and lipodystrophy in HIV-infected, protease inhibitor (Pl)-treated men with hypercholesterolaemia. Methods: A randomized, placebo-controlled, 16-week study was carried out on 33 HIV-infected, hypercholesterolaemic men (fasting total cholesterol > 6.5mmol/L) on PI-containing therapy. Patients commenced dietary assessment and advice at week 0 and were randomized to 12 weeks pravastatin (40 mg each night) or placebo from week 4. The primary endpoint was the time-weighted change (TWAUC) in total cholesterol from week 0. Secondary endpoints included TWAUC cholesterol from week 4 (start of pravastatin), total and regional body fat, fasting lipids, glucose, insulin, and markers of cardiovascular risk. Results: Of 33 men randomized (pravastatin n = 16, mean age 48 years), 31 completed the study. Groups were matched for baseline cholesterol and body composition. Although there was no significant between-group difference in TWAUC cholesterol from week 0 (pravastatin -0.6 ± 1.0 versus placebo -0.4 ± 1.0 mmol/L/week; P = 0.8), TWAUC cholesterol from week 4 decreased more in the pravastatin group (-0.8 ± 1.0 versus -0.3 ± 0.9 mmol/L/week; P = 0.04). Neither triglycerides nor dietary intake changed. Subcutaneous fat increased significantly with pravastatin (+0.72 ± 1.55 versus +0.19 ± 0.48 kg change in limb fat, P < 0.04; +5.2 ± 8.7 versus -1.3 ± 13.7 cm<sup>2</sup> change in abdominal subcutaneous fat, P = 0.02). Apart from homocystine, which decreased in the pravastatin group, there were no significant differences in other cardiovascular, lipid or glucose parameters. Conclusions: Despite limited effects on cholesterol, 12 weeks use of pravastatin 40 mg each night in HIV-infected men with hypercholesterolaemia resulted in significant increases in subcutaneous fat.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>États-Unis</li></country><region><li>Massachusetts</li><li>Nouvelle-Galles du Sud</li><li>Île-de-France</li></region><settlement><li>Paris</li><li>Sydney</li></settlement></list><tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W. G." last="Mallon">Patrick W. G. Mallon</name></region><name sortKey="Carr, Andrew" sort="Carr, Andrew" uniqKey="Carr A" first="Andrew" last="Carr">Andrew Carr</name><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A." last="Cooper">David A. Cooper</name><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A." last="Cooper">David A. Cooper</name><name sortKey="Feneley, Michael P" sort="Feneley, Michael P" uniqKey="Feneley M" first="Michael P." last="Feneley">Michael P. Feneley</name><name sortKey="Kent Hughes, Julia" sort="Kent Hughes, Julia" uniqKey="Kent Hughes J" first="Julia" last="Kent-Hughes">Julia Kent-Hughes</name><name sortKey="Kovacic, Jason C" sort="Kovacic, Jason C" uniqKey="Kovacic J" first="Jason C." last="Kovacic">Jason C. Kovacic</name><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W. G." last="Mallon">Patrick W. G. Mallon</name><name sortKey="Miller, John" sort="Miller, John" uniqKey="Miller J" first="John" last="Miller">John Miller</name><name sortKey="Norris, Richard" sort="Norris, Richard" uniqKey="Norris R" first="Richard" last="Norris">Richard Norris</name><name sortKey="Samaras, Katherine" sort="Samaras, Katherine" uniqKey="Samaras K" first="Katherine" last="Samaras">Katherine Samaras</name></country><country name="France"><region name="Île-de-France"><name sortKey="Samaras, Katherine" sort="Samaras, Katherine" uniqKey="Samaras K" first="Katherine" last="Samaras">Katherine Samaras</name></region><name sortKey="Boccara, Franck" sort="Boccara, Franck" uniqKey="Boccara F" first="Franck" last="Boccara">Franck Boccara</name><name sortKey="Capeau, Jacqueline" sort="Capeau, Jacqueline" uniqKey="Capeau J" first="Jacqueline" last="Capeau">Jacqueline Capeau</name><name sortKey="Capeau, Jacqueline" sort="Capeau, Jacqueline" uniqKey="Capeau J" first="Jacqueline" last="Capeau">Jacqueline Capeau</name><name sortKey="Capeau, Jacqueline" sort="Capeau, Jacqueline" uniqKey="Capeau J" first="Jacqueline" last="Capeau">Jacqueline Capeau</name><name sortKey="Capeau, Jacqueline" sort="Capeau, Jacqueline" uniqKey="Capeau J" first="Jacqueline" last="Capeau">Jacqueline Capeau</name><name sortKey="Gharakhanian, Shahin" sort="Gharakhanian, Shahin" uniqKey="Gharakhanian S" first="Shahin" last="Gharakhanian">Shahin Gharakhanian</name></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Gharakhanian, Shahin" sort="Gharakhanian, Shahin" uniqKey="Gharakhanian S" first="Shahin" last="Gharakhanian">Shahin Gharakhanian</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009F83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009F83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:06-0243815
|texte= Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men : a randomized, placebo-controlled study. Commentary
}}
| This area was generated with Dilib version V0.6.33. |  |